Updates in the diagnosis and management of Takayasu’s arteritis

References

• Takayasu M. A case with curious change in the central retinal vessel. Nippon Ganka Gakkai Zasshi (J Jpn Ophthalmol Soc). 1908;12,554–12,555
   Google Scholar
• Sugiyama K, Ijiri S, Tagawa S, et al. Takayasu disease on the centenary of its discovery. Jpn J Ophthalmol. 2009;53(2):81–91.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Sano K. Pulseless disease. J Neuropathol Clin Neurol. 1951;1(1):37–47.
   PubMedGoogle Scholar
• Inada K, Yokoyama T, Nakaya R. Atypical Coarctation of the Aorta. Angiology; 1963;14:506–517
   Google Scholar
• Ueda H, Ito I, Okada R, et al. Aortic arch syndrome with special reference to pulseless disease and its variants. Jpn Heart J. 1963;4(3):224–232.
   PubMedGoogle Scholar
• Nasu T. [Pathohistological changes and etiology of obstructive productive arteritis]. Nihon Rinsho. 1968;26(11):3292–3299.
   PubMedGoogle Scholar
• Judge RD, Currier RD, Gracie WA, et al. Takayasu’s arteritis and the aortic arch syndrome. Am J Med. 1962;32(3):379–392.
   PubMed Web of Science ®Google Scholar
• Group JCSJW. Guideline for management of vasculitis syndrome (JCS 2008). Japanese Circulation Society. Circ J. 2011;75(2):474–503.
   PubMed Web of Science ®Google Scholar
• Saritas F, Donmez S, Direskeneli H, et al. The epidemiology of Takayasu arteritis: a hospital-based study from northwestern part of Turkey. Rheumatol Int. 2016;36(7):911–916.
   PubMed Web of Science ®Google Scholar
• Jang SY, Seo SR, Park SW, et al. Prevalence of Takayasu’s arteritis in Korea. Clin Exp Rheumatol. 2018;111(2):163–164.
   Google Scholar
• Sanchez-Alvarez C, Crowson CS, Koster MJ, et al. Prevalence of Takayasu Arteritis: a Population-based Study. J Rheumatol. 2021;48(6):952.
   PubMed Web of Science ®Google Scholar
• Hall S, Barr W, Lie JT, et al. Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore). 1985;64(2):89–99.
   PubMed Web of Science ®Google Scholar
• Onen F, Akkoc N. Epidemiology of Takayasu arteritis. Presse Med. 2017;46(7–8):e197–e203.
   PubMed Web of Science ®Google Scholar
• Isohisa I, Numano F, Maezawa H, et al. HLA-Bw52 in Takayasu disease. Tissue Antigens. 1978;12(4):246–248.
   PubMedGoogle Scholar
• Numano F, Isohisa I, Maezawa H, et al. HL-A antigens in Takayasu’s disease. Am Heart J. 1979;98(2):153–159.
   PubMed Web of Science ®Google Scholar
• Terao C. Revisited HLA and non-HLA genetics of Takayasu arteritis–where are we? J Hum Genet. 2016;61(1):27–32.
   PubMed Web of Science ®Google Scholar
• Yajima M, Numano F, Park YB, et al. Comparative studies of patients with Takayasu arteritis in Japan, Korea and India–comparison of clinical manifestations, angiography and HLA-B antigen. Jpn Circ J. 1994;58(1):9–14.
   PubMedGoogle Scholar
• Kitamura H, Kobayashi Y, Kimura A, et al. Association of clinical manifestations with HLA-B alleles in Takayasu arteritis. Int J Cardiol. 1998;66(Suppl 1):S121–6.
   PubMed Web of Science ®Google Scholar
• Takamura C, Ohhigashi H, Ebana Y, et al. New human leukocyte antigen risk allele in Japanese patients with Takayasu arteritis. Circ J. 2012;76(7):1697–1702.
   PubMed Web of Science ®Google Scholar
• Nakajima T, Yoshifuji H, Shimizu M, et al. A novel susceptibility locus in the IL12B region is associated with the pathophysiology of Takayasu arteritis through IL-12p40 and IL-12p70 production. Arthritis Res Ther. 2017;19(1):197.
   PubMed Web of Science ®Google Scholar
• Ortiz-Fernandez L, Saruhan-Direskeneli G, Alibaz-Oner F, et al. Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. Am J Hum Genet. 2021;108(1):84–99.
   PubMed Web of Science ®Google Scholar
• Desbois AC, Ciocan D, Saadoun D, et al. Specific microbiome profile in Takayasu’s arteritis and giant cell arteritis. Sci Rep. 2021;11(1):5926.
   PubMed Web of Science ®Google Scholar
• Pedreira ALS, Santiago MB. Association between Takayasu arteritis and latent or active Mycobacterium tuberculosis infection: a systematic review. Clin Rheumatol. 2020;39(4):1019–1026.
   PubMed Web of Science ®Google Scholar
• Zaldivar Villon MLF, de la Rocha JAL, Espinoza LR. Takayasu Arteritis: recent Developments. Curr Rheumatol Rep. 2019;21(9):45.
   PubMed Web of Science ®Google Scholar
• Harky A, Fok M, Balmforth D, et al. Pathogenesis of large vessel vasculitis: implications for disease classification and future therapies. Vasc Med. 2019;24(1):79–88.
   PubMed Web of Science ®Google Scholar
• Seko Y, Minota S, Kawasaki A, et al. Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu’s arteritis. J Clin Invest. 1994;93(2):750–758.
   PubMed Web of Science ®Google Scholar
• Samson M, Ly KH, Tournier B, et al. Involvement and prognosis value of CD8(+) T cells in giant cell arteritis. J Autoimmun. 2016;72:73–83.
   PubMed Web of Science ®Google Scholar
• Ponte C, Agueda AF, Luqmani RA. Clinical features and structured clinical evaluation of vasculitis. Best Pract Res Clin Rheumatol. 2018;32(1):31–51.
   PubMed Web of Science ®Google Scholar
• Ishikawa K. Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu’s arteriopathy. J Am Coll Cardiol. 1988;12(4):964–972.
   PubMed Web of Science ®Google Scholar
• Tomelleri A, Campochiaro C, Sartorelli S, et al. Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis. Scand J Rheumatol. 2019;48(6):482–490.
   PubMed Web of Science ®Google Scholar
• Li J, Sun F, Chen Z, et al. The clinical characteristics of Chinese Takayasu’s arteritis patients: a retrospective study of 411 patients over 24 years. Arthritis Res Ther. 2017;19(1):107.
   PubMed Web of Science ®Google Scholar
• Kwon OC, Lee SW, Park YB, et al. Extravascular manifestations of Takayasu arteritis: focusing on the features shared with spondyloarthritis. Arthritis Res Ther. 2018;20(1):142.
   PubMed Web of Science ®Google Scholar
• Reny JL, Paul J-F, Lefèbvre C, et al. Association of Takayasu’s arteritis and Crohn’s disease. Results of a study on 44 Takayasu patients and review of the literature. Ann Med Internet (Paris). 2003;154(2):85–90.
   PubMedGoogle Scholar
• Sy A, Khalidi N, Dehghan N, et al. Vasculitis in patients with inflammatory bowel diseases: a study of 32 patients and systematic review of the literature. Semin Arthritis Rheum. 2016;45(4):475–482.
   PubMed Web of Science ®Google Scholar
• Sagar S, Kar S, Gupta A, et al. Ocular changes in Takayasu’s arteritis in India. Jpn J Ophthalmol. 1994;38(1):97–102.
   PubMed Web of Science ®Google Scholar
• Kiyosawa M, Baba T. Ophthalmological findings in patients with Takayasu disease. Int J Cardiol. 1998;66(Suppl 1):S141–7. discussion S149.
   PubMed Web of Science ®Google Scholar
• Baba T, Itakura K, Tanaka R, et al. Importance of fluorescein angiographic study in evaluating early retinal changes in Takayasu disease. Jpn J Ophthalmol. 1999;43(6):546–552.
   PubMed Web of Science ®Google Scholar
• Chun YS, Park SJ, Park IK, et al. The clinical and ocular manifestations of Takayasu arteritis. Retina. 2001;21(2):132–140.
   PubMed Web of Science ®Google Scholar
• Peter J, David S, Danda D, et al. Ocular manifestations of Takayasu arteritis: a cross-sectional study. Retina. 2011;31(6):1170–1178.
   PubMed Web of Science ®Google Scholar
• Comarmond C, Dessault O, Devaux J-Y, et al. Myocardial perfusion imaging in Takayasu arteritis. J Rheumatol. 2013;40(12):2052–2060.
   PubMed Web of Science ®Google Scholar
• Xi X, Du J, Liu J, et al. Pulmonary artery involvement in Takayasu arteritis: a retrospective study in Chinese population. Clin Rheumatol. 2021;40(2):635–644.
   PubMed Web of Science ®Google Scholar
• Yazici A, Kaymaz-Tahra S, Ozdemir Isik O, et al. The prevalence of non-vascular pulmonary manifestations in Takayasu’s Arteritis patients: a Retrospective multi-centred Turkish cohort study. Scand J Rheumatol. 2022;51(4):304–308.
   PubMed Web of Science ®Google Scholar
• Sharma BK, Siveski-Iliskovic N, Singal PK. Takayasu arteritis may be underdiagnosed in North America. Can J Cardiol. 1995;11(4):311–316.
   PubMed Web of Science ®Google Scholar
• Arend WP, Michel BA, Bloch DA, et al. The American college of rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129–1134.
   PubMed Web of Science ®Google Scholar
• Seeliger B, Sznajd J, Robson JC, et al. Are the 1990 American college of rheumatology vasculitis classification criteria still valid? Rheumatology (Oxford). 2017;56(7):1154–1161.
   PubMed Web of Science ®Google Scholar
• Andrews J, Al-Nahhas A, Pennell DJ, et al. Non-invasive imaging in the diagnosis and management of Takayasu’s arteritis. Ann Rheum Dis. 2004;63(8):995–1000.
   PubMed Web of Science ®Google Scholar
• Grayson PC, Alehashemi S, Bagheri AA, et al. (18) F-fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol. 2018;70(3):439–449.
   PubMed Web of Science ®Google Scholar
• Webb M, Chambers A, AL-Nahhas A, et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging. 2004;31(5):627–634.
   PubMed Web of Science ®Google Scholar
• Tombetti E, Mason JC. Application of imaging techniques for Takayasu arteritis. Presse Med. 2017;46(7–8 Pt 2):e215–e223.
   PubMed Web of Science ®Google Scholar
• Barra L, Kanji T, Malette J, et al. Imaging modalities for the diagnosis and disease activity assessment of Takayasu’s arteritis: a systematic review and meta-analysis. Autoimmun Rev. 2018;17(2):175–187.
   PubMed Web of Science ®Google Scholar
• Lottspeich C, Dechant C, Köhler A, et al. Assessment of disease activity in Takayasu arteritis: potential role of contrast-enhanced ultrasound. Ultraschall Med. 2019;40(5):638–645.
   PubMed Web of Science ®Google Scholar
• Ma LY, Li CL, Ma LL, et al. Value of contrast-enhanced ultrasonography of the carotid artery for evaluating disease activity in Takayasu arteritis. Arthritis Res Ther. 2019;21(1):24.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y-H, Tian X-P, et al. Contrast-enhanced ultrasound for evaluating arteritis activity in Takayasu arteritis patients. Clin Rheumatol. 2020;39(4):1229–1235.
   PubMed Web of Science ®Google Scholar
• Eichhorn J, Sima D, Thiele B, et al. Anti-endothelial cell antibodies in Takayasu arteritis. Circulation. 1996;94(10):2396–2401.
   PubMed Web of Science ®Google Scholar
• Park MC, Park YB, Jung SY, et al. Anti-endothelial cell antibodies and antiphospholipid antibodies in Takayasu’s arteritis: correlations of their titers and isotype distributions with disease activity. Clin Exp Rheumatol. 2006;24(2 Suppl 41):S10–6.
   PubMed Web of Science ®Google Scholar
• Dogan S, Piskin O, Solmaz D, et al. Markers of endothelial damage and repair in Takayasu arteritis: are they associated with disease activity? Rheumatol Int. 2014;34(8):1129–1138.
   PubMed Web of Science ®Google Scholar
• Harada M, Yoshida H, Mitsuyama K, et al. Aortitis syndrome (Takayasu’s arteritis) with cataract and elevated serum level of vascular endothelial growth factor. Scand J Rheumatol. 1998;27(1):78–79.
   PubMed Web of Science ®Google Scholar
• Kuroda T, Ueno M, Sato H, et al. A case of Takayasu arteritis complicated with glomerulonephropathy mimicking membranoproliferative glomerulonephritis: a case report and review of the literature. Rheumatol Int. 2006;27(1):103–107.
   PubMed Web of Science ®Google Scholar
• Alibaz-Oner F, Yentür SP, Saruhan-Direskeneli G, et al. Serum cytokine profiles in Takayasu’s arteritis: search for biomarkers. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-32–5.
   Web of Science ®Google Scholar
• Arraes AE, de Souza AW, Mariz HA, et al. [(18)F-Fluorodeoxyglucose positron emission tomography and serum cytokines and matrix metalloproteinases in the assessment of disease activity in Takayasu’s arteritis] . Rev Bras Reumatol Engl Ed. 2016;56(4): 299–308.
   PubMedGoogle Scholar
• Sun Y, Ma L, Yan F, et al. MMP-9 and IL-6 are potential biomarkers for disease activity in Takayasu’s arteritis. Int J Cardiol. 2012;156(2):236–238.
   PubMed Web of Science ®Google Scholar
• Wen X, Hou R, Xu K, et al. Pentraxin 3 is more accurate than C-reactive protein for Takayasu arteritis activity assessment: a systematic review and meta-analysis. PLoS One. 2021;16(2):e0245612.
   PubMed Web of Science ®Google Scholar
• Misra R, Danda D, Rajappa SM, et al. Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford). 2013;52(10):1795–1801.
   PubMed Web of Science ®Google Scholar
• Misra DP, Rathore U, Patro P, et al. Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis. Clin Rheumatol. 2021;40(11):4391–4416.
   PubMed Web of Science ®Google Scholar
• de Franciscis S, Serra R, Luongo A, et al. The management of Takayasu’s arteritis: personal experience. Ann Vasc Surg. 2007;21(6):754–760.
   PubMed Web of Science ®Google Scholar
• Wu C, Sun Y, Cui X, et al. Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis. Ther Adv Chronic Dis. 2020;11:2040622320975233.
   Web of Science ®Google Scholar
• Mertz P, Kleinmann J-F, Lambert M, et al. Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: results of a multicenter open-label prospective study. Autoimmun Rev. 2020;19(10):102634.
   PubMed Web of Science ®Google Scholar
• Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77(3):348–354.
   PubMed Web of Science ®Google Scholar
• Nakaoka Y, Isobe M, Tanaka Y, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology (Oxford). 2020;59(9):2427–2434.
   PubMed Web of Science ®Google Scholar
• Prieto-Pena D, Bernabeu P, Vela P, et al. Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review. Ther Adv Musculoskelet Dis. 2021;13:1759720X211020917.
   PubMed Web of Science ®Google Scholar
• Isobe M, Maejima Y, Saji M, et al. Evaluation of tocilizumab for intractable Takayasu arteritis and (18)F-fluorodeoxyglucose-positron emission tomography for detecting inflammation under tocilizumab treatment. J Cardiol. 2021;77(5):539–544.
   PubMed Web of Science ®Google Scholar
• Wu S, Kong X, Cui X, et al. Effectiveness and safety of tocilizumab in patients with refractory or severe Takayasu’s arteritis: a prospective cohort study in a Chinese population. Joint Bone Spine. 2021;88(5):105186.
   PubMed Web of Science ®Google Scholar
• Langford CA, Cuthbertson D, Ytterberg SR, et al. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis Rheumatol. 2017;69(4):846–853.
   PubMed Web of Science ®Google Scholar
• Pazzola G, Muratore F, Pipitone N, et al. Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. Rheumatology (Oxford). 2018;57(7):1151–1155.
   PubMed Web of Science ®Google Scholar
• Rongyi C, Zongfei J, Jiang L, et al. Effect of hydroxychloroquine on angiographic progression in routine treatment of Takayasu arteritis. Mod Rheumatol. 2021;31(6):1135–1141.
   PubMed Web of Science ®Google Scholar
• Li G, Liu F, Wang Y, et al. Effects of resistance exercise on treatment outcome and laboratory parameters of Takayasu arteritis with magnetic resonance imaging diagnosis: a randomized parallel controlled clinical trial. Clin Cardiol. 2020;43(11):1273–1278.
   PubMed Web of Science ®Google Scholar
• Shao N, Jia H, Li Y, et al. Curcumin improves treatment outcome of Takayasu arteritis patients by reducing TNF-alpha: a randomized placebo-controlled double-blind clinical trial. Immunol Res. 2017;65(4):969–974.
   PubMed Web of Science ®Google Scholar
• Maz M, Chung SA, Abril A, et al. 2021 american college of rheumatology/vasculitis foundation guideline for the management of giant cell arteritis and Takayasu Arteritis. Arthritis Care Res (Hoboken). 2021;73(8):1071–1087.
   PubMed Web of Science ®Google Scholar
• Mutoh T, Shirai T, Fujii H, et al. Insufficient Use of Corticosteroids without Immunosuppressants Results in Higher Relapse Rates in Takayasu Arteritis. J Rheumatol. 2020;47(2):255–263.
   PubMed Web of Science ®Google Scholar
• Alibaz-Oner F, Kaymaz-Tahra S, Bayındır Ö, et al. Biologic treatments in Takayasu’s Arteritis: a comparative study of tumor necrosis factor inhibitors and tocilizumab. Semin Arthritis Rheum. 2021;51(6):1224–1229.
   PubMed Web of Science ®Google Scholar
• Kwon OC, Oh JS, Park M-C, et al. Statins reduce relapse rate in Takayasu arteritis. Int J Cardiol. 2019;287:111–115.
   PubMed Web of Science ®Google Scholar
• Laurent C, Prieto-González S, Belnou P, et al. Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis. Sci Rep. 2021;11(1):14404.
   PubMed Web of Science ®Google Scholar
• Kelesoglu Dincer AB, Kiliç L, Erden A, et al. Imaging modalities used in diagnosis and follow-up of patients with Takayasu’s arteritis. Turk J Med Sci. 2021;51(1):224–230.
   PubMed Web of Science ®Google Scholar
• Walter MA, Melzer RA, Schindler C, et al. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging. 2005;32(6):674–681.
   PubMed Web of Science ®Google Scholar
• Zheng T, Zhu S, Ou JF, et al. Treatment with corticosteroid and/or immunosuppressive agents before surgery can effectively improve the surgical outcome in patients with Takayasu’s Arteritis. J Invest Surg. 2019;32(3):220–227.
   PubMed Web of Science ®Google Scholar
• Fields CE, Bower TC, Cooper LT, et al. Takayasu’s arteritis: operative results and influence of disease activity. J Vasc Surg. 2006;43(1):64–71.
   PubMed Web of Science ®Google Scholar